Vast Clinical Experience
Maximal accuracy. Minimal false positive.
Clinical Validation in the Assuta Study
A retrospective analysis of 100 cases from the ‘TIGAR’ program at Assuta Hospital, Israel, was conducted as part of the Ministry of Health’s screening pilot.
>97%
Accuracy on nodules as small as 3mm
0.2
false positives Per case
These outstanding results have been added to previous successful validations on over 2,000 real cases from LIDC and Israeli hospital databases, further emphasizing the effectiveness of our approach.
Pivotal study at MGH underway, moving toward FDA approval
Participating in the exclusive iDNA comparative study
Success in this study will establish our superiority in detecting early-stage cancer, enabling us to lead a paradigm shift in the field.
1
4ITLR baseline
Nodule detection & selection level
Version upgrade
2
UKLS
Participant classification level
Version upgrade
3
4ITLR baseline
Participant Diseas / clinical outcome level
Version upgrade
4
Completed 4ITLR
Participant Diseas / clinical outcome level
Version upgrade
